Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
about
TReP-132 controls cell proliferation by regulating the expression of the cyclin-dependent kinase inhibitors p21WAF1/Cip1 and p27Kip1Oral exposure to bisphenol a increases dimethylbenzanthracene-induced mammary cancer in ratsIntratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancerEndocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogensPhosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancerFarnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways.Development of Companion DiagnosticsCooperating transcription factors mediate the function of estrogen receptorEstrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategiesFrom bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?Functional implications of altered subcellular localization of PELP1 in breast cancer cells.Growth factor regulation of estrogen receptor coregulator PELP1 functions via Protein Kinase A pathwaySignificance of ER-Src axis in hormonal therapy resistanceThe impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasisSustained proliferation in cancer: Mechanisms and novel therapeutic targetsTamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancerDigital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune responseTranscriptional regulation prediction of antiestrogen resistance in breast cancer based on RNA polymerase II binding data.Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signalingGenomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer.Conjugated linoleic acid induces apoptosis through estrogen receptor alpha in human breast tissue.Novel roles for ERK5 and cofilin as critical mediators linking ERα-driven transcription, actin reorganization, and invasiveness in breast cancer.Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.ZEB1 induces ER-α promoter hypermethylation and confers antiestrogen resistance in breast cancer.A multifactorial 'Consensus Signature' by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer.Proteomic analysis of pathways involved in estrogen-induced growth and apoptosis of breast cancer cells.Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) familyRoles of prohibitin in growth control and tumor suppression in human cancersClinical outcome of adjuvant endocrine treatment according to Her-2/neu status in breast cancer.The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cellsEffect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo.PTIP associated protein 1, PA1, is an independent prognostic factor for lymphnode negative breast cancer.Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumorsAccumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer.NFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms.Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.The role of Nanog expression in tamoxifen-resistant breast cancer cells
P2860
Q24529076-FFAAAEA7-4706-4AAE-AD81-F27B6944B34AQ24657393-1DF8A4B4-B7A5-4651-BE21-5D52580F1159Q24794121-27EBC700-E150-49B9-AD48-FDA8A232AEA1Q24796233-7C79D151-650C-426F-BA68-FC6F8CE23055Q24813594-6A191D21-F29F-47E9-AE30-66A1A6D8E76FQ24813627-D1D89F61-56CB-46A0-90C1-D8F6C7DC5D30Q25257588-EE1FA21B-DA7E-4BC5-8DB2-064D81FCF155Q26774670-49A2F7F5-0E7B-49CB-8564-B3958A2830E9Q26996464-7AA6934D-48B9-498E-B219-A18A3DD01211Q27851630-EBBBFEBA-57AA-4010-98A2-D809AABB4CD1Q28072897-BF324C81-2F53-4CFA-88DA-E4160DF87906Q28084982-EE6E8C1F-48D7-4E0E-9D73-4311C9625B06Q28270490-ABDB3F49-A7D3-4AC2-861A-B92A5C5237F4Q28281599-C74C5571-3EE5-402B-972D-88E5F02163E5Q28301805-E3112AD5-F9E5-45EB-BA79-6AD6906AA766Q28388257-0704CD7C-AE77-4B5E-82B1-ED80F32024A6Q28396388-3D8484F3-170E-4675-9350-435636A9CFCCQ28481232-10BA91E8-DE13-4815-B884-A8FB7550871CQ28533543-F46E2C76-7D4B-40C2-BF23-1A74433ADF7AQ30763243-9C79918F-0D9A-4D94-ABAE-F57721E7C975Q31132241-BE9F3F20-C28E-43EF-B740-11343CD668BDQ33239655-47F2F30F-3B3F-48EC-98FE-FB63B597F685Q33354773-3BA61044-4991-4610-AE5A-5C4345ECF832Q33610918-17DD2D47-FB8D-4F21-AEDE-A6DCA255B01AQ33703311-DD2E038B-2DDC-42E9-9545-F9C530F643D8Q33815885-75F431AF-1E5F-41DD-9DB4-34070B6FAFACQ33914753-5F797919-7AC6-4602-A579-F471DEA35B52Q33954542-10F006D0-7623-4E3B-9D1D-85D456581F19Q34013708-452B9C8D-9058-425A-B894-733212FAEDDCQ34497715-38C83927-296A-44B3-AB19-E8AAE5C53EDAQ34999423-2681FC34-9F49-40AD-8FA4-EF8D49366A76Q35000256-C4589E62-ECC9-4AAF-BDC3-44E984E754DEQ35012724-1C7B8F5A-657B-444F-A9DB-BAB00C3B7776Q35049096-08E35964-EE52-4114-8EB0-48907AE94157Q35110068-2BD2FD26-F53B-4F4B-8ED4-7094597ED534Q35161695-BA63AF51-DA83-43A3-94C0-A6885C9FE9A1Q35469769-6D41C790-811A-479E-BCA1-126FE4666CA3Q35558134-5F743671-667C-4942-98EB-713244970CB3Q35605783-B51B9B5E-F245-41A4-B88F-BD4898BA13F1Q35703398-BA58B701-BEA7-4D9D-8B37-CAD03F46A496
P2860
Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Breast cancer endocrine resist ...... oregulators modulate response.
@ast
Breast cancer endocrine resist ...... oregulators modulate response.
@en
type
label
Breast cancer endocrine resist ...... oregulators modulate response.
@ast
Breast cancer endocrine resist ...... oregulators modulate response.
@en
prefLabel
Breast cancer endocrine resist ...... oregulators modulate response.
@ast
Breast cancer endocrine resist ...... oregulators modulate response.
@en
P2093
P1476
Breast cancer endocrine resist ...... coregulators modulate response
@en
P2093
C Kent Osborne
Jiang Shou
Rachel Schiff
Suleiman Massarweh
P304
P407
P433
P577
2003-01-01T00:00:00Z